펩젠 (PEPG) 주가

펩젠(PEPG)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $2.85 (-4.04%), 시가총액 $107.21M, 52주 범위 $1.01 ~ $7.17.

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.

핵심 지표

• 현재가: $2.85 (-4.04%)
• 시가총액: $107.21M
• 52주 최저~최고: $1.01 ~ $7.17
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NAS

펩젠의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.

펩젠 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 매수 (4.2 / 5)

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 0.83
• 순이익률: 0.00%
• 영업이익률: 0.00%

자주 묻는 질문